Elm

& C

arlto

n S

tree

tsB

uffa

lo, N

Y 1

4263

WWW.ROSWELLPARK.EDU/CMECONFERENCES

2956

4 (1

2/15

)

Location

Registration

L O C A T I O N

Roswell Park Cancer Institute - Research Studies Center, Elm and Carlton Sts, Buffalo, NY 14263

The Research Studies Center is located across the street from the hospital building on Elm & Carlton Streets. Enter building from Carlton Street. Complimentary parking is available in the hospital parking ramp on Elm & Carlton. Bring your ticket to the registration desk for validation. Metered parking is available on the street. Look for the payment kiosks along Elm & Virginia Streets.

For driving directions, www.roswellpark.org/directions-maps.

R E G I S T R A T I O N

ONLINE: www.RoswellPark.edu/CMEConferences

Fees (includes breakfast, coffee break and lunch):Physicians and pharmacists . . . . . . . . . . . . . . . . . . . . . $50.00 NPs, PAs and other healthcare providers . . . . . . . . . . . $25.00Pharmaceutical Industry Employees . . . . . . . . . . . . . . $200.00Fellows, Residents and Medical Students . . . . . . . . . . .FREE

Roswell Park Cancer Institute reserves the right to cancel the program for any reason. Registrants will be notified. No refunds will be issued for cancellations received after January 12, 2016. There will be a $10 administrative fee deducted for any cancellations.

If you have any questions, contact Denise Hammell at denise.hammell@roswellpark.org or (716) 845-5706.

RE

TUR

N S

ER

VIC

E R

EQ

UE

STE

D

SATURDAY, JANUARY 16, 20168:00AM – 1:30PM

RESEARCH STUDIES CENTERROSWELL PARK CANCER INSTITUTE

2016 Hematological Malignancies Conference

INCORPORATING TARGETED THERAPIES IN BLOOD-RELATED DISORDERS

Roswell Park FacultyR O S W E L L P A R K F A C U L T Y

Bora Baysal, MD, PhD Associate Professor of Oncology Department of Pathology & Laboratory Medicine

Seema Bhat, MD Assistant Professor of Oncology Lymphoma/Myeloma Service Department of Medicine

Annemarie Block, PhD, FACMG Laboratory Director, Cytogenetics Lab Department of Pathology & Laboratory Medicine Associate Professor of Oncology

George Chen, MD Assistant Professor of Oncology Department of Medicine/BMT

Elizabeth Griffiths, MD Associate Professor of Oncology/Leukemia Service Department of Medicine

Francisco Hernandez-Ilizaliturri, MD Professor of Oncology Department of Medicine Assistant Professor of Immunology Department of Immunology Clinical Chief Lymphoma/Myeloma Service

Sarah Holstein, MD, PhD Associate Professor of Oncology Lymphoma/Myeloma Service Department of Medicine

Philip McCarthy, MD Professor of Oncology Department of Medicine Director, Blood & Marrow Transplant Program

Vishala Neppalli, MD Assistant Professor of Oncology Department of Pathology & Laboratory Medicine

Sheila Jani Sait, PhD Assistant Director of Clinical Cytogenetics Laboratory and Research Coordinator Assistant Professor of Oncology Department of Pathology & Laboratory Medicine

Program

Guest Speakers

Description

Educational Objectives

D E S C R I P T I O N

This program is designed for hematologists, oncologists, nurses, nurse practitioners, physician assistants, and other providers specializing in hematology/oncology practice. New clinically-relevant research findings are reported each year, and while community oncologists may learn about these findings in a timely manner, it may take months before strategies to effectively put this new knowledge into practice are developed. This conference will provide opportunities to focus on the most clinically-relevant research findings presented at recent national events, in order to better understand how to apply this information in specific patient cases.

E D U C A T I O N A L O B J E C T I V E S

Following this program, participants should be able to:

• Determine what signaling pathways are clinically-relevant to target in subtypes of Non-Hodgkin’s Lymphoma.

• Explain the common side effects associated with the use of novel agents approved for the treatment of B-cell lymphoma, and how they are optimally managed.

• Determine the role of checkpoint inhibitors in B-cell lymphoma and Hodgkin’s disease.

• Identify which clinical parameters or biomarkers aid physicians in the up-front treatment selection in multiple myeloma (MM) patients.

• Describe the role of maintenance therapy in MM patients and how long maintenance therapy is necessary.

• Explain the role of novel agents in the treatment of myeloproliferative disorders (MPD).

• Discuss potential targeted pathways to prevent the progression of myelodysplastic syndromes (MDS) into acute myeloid leukemia (AML).

• Explain the underlying pathogenesis of MDS and assess its impact on clinical practice.

8:35 Treatment-Paradigm Shifts in the Management of Hodgkin’s Lymphoma Francisco Hernandez-Ilizaliturri, MD

9:05 Lymphoma Clinical Practice Round Table and Tumor Board Moderator: Vishala Neppalli, MD Table Participants: Drs. Seema Bhat, Francisco Hernandez-Ilizaliturri, Brian Hill, Philip McCarthy and Sheila Jani Sait

9:35 Break

MYELOMA Program Chair: Philip McCarthy, MD

9:50 Clinical Practice Changes in the Front-Line Management of Transplant Eligible Multiple Myeloma Patients: the Evolving Role of Post-Transplant Maintenance Programs Donna Reece, MD, FRCPC

10:20 Clinical Practice Changes in the Front-Line Management of Transplant Ineligible or Relapsed/Refractory Multiple Myeloma patients Sarah Holstein, MD, PhD

10:50 Myeloma Clinical Practice Round Table and Tumor Board Moderator: Bora Baysal, MD, PhD Table Participants: Drs. Sarah Holstein, Philip McCarthy and Donna Reece

11:20 Lunch Break (Audience to pick up lunch and return to their seats)

LEUKEMIA Program Chair: Elizabeth Griffiths, MD

11:50 Clinical Practice Changes in the Diagnosis and Management of Patients with Myeloproliferative Disorders (MPD) Alison Rae Moliterno, MD

AccreditationA C C R E D I T A T I O N - A M A , A A N P , A C P E

Roswell Park Cancer Institute is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. Roswell Park Cancer Institute designates this live educational activity for a maximum of 4.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is approved for 2.5 contact hour(s) of continuing education by the American Association of Nurse Practitioners. Program ID 15122022. This program was planned in accordance with AANP CE Standards and Policies.

The University at Buffalo School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The “2016 Hematological Malignancies Conference: Incorporating Targeted Therapies in Blood-Related Disorders”, ACPE# 0044-9999-15-091-L01-P, has been accredited as a knowledge-based activity. Pharmacists will earn 4.5 Contact Hours or 0.45 CEUs. of continuing education credit. Credit will be uploaded to the CPE Monitor for those who attend the full session and complete a CE attendance document. No partial credit will be awarded.

P R O G R A M

7:30 am Registration

8:00 Introduction and Opening Remarks Francisco Hernandez-Ilizaliturri, MD

LYMPHOMA Program Chair: Francisco Hernandez-Ilizaliturri, MD

8:05 Emerging Agents in the Management of Non-Hodgkin’s Lymphoma (NHL) Brian Hill, MD, PhD

Acknowledgments

12:20 pm Updates in the Management of Myelodysplastic Syndromes (MDS) Elizabeth Griffiths, MD

12:50 Leukemia Clinical Practice Round Table and Tumor Board Moderator: Vishala Neppalli, MD Table Participants: Drs. Annemarie Block, George Chen, Elizabeth Griffiths, and Alison Rae Moliterno

1:20 Closing Remarks and Sponsor Acknowledgments

1:30 Adjourn

I N V I T E D S P E A K E R S

Brian Hill, MD, PhD Staff Physician Department of Hematology and Medical Oncology Taussig Cancer Institute of the Cleveland Clinic Cleveland, OH

Alison Rae Moliterno, MD Associate Professor of Medicine Division of Hematology Johns Hopkins School of Medicine Baltimore, MD

Donna Reece, MD, FRCPC Professor of Medicine Director, Program for Multiple Myeloma and Related Diseases Princess Margaret Cancer Centre Toronto, Ontario Canada

A C K N O W L E D G M E N T S

This program is supported in part by educational grants from • Amgen • Seattle Genetics • Celgene • Gilead